These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 18819710)

  • 21. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
    Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.
    Ho AD; Lipp T; Ehninger G; Meyer P; Freund M; Hunstein W
    Cancer Treat Rep; 1986 Aug; 70(8):1025-7. PubMed ID: 3460698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
    Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitoxantrone in combination with etoposide and cytarabine for treatment of poor prognosis acute non lymphoid leukemia patients.
    Tribalto M; Cantonetti M; Catalano G; Del Poeta G; Masi M; Pastore S; Pisani F; Stasi R; Papa G
    Haematologica; 1991; 76(5):402-5. PubMed ID: 1806445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
    Daenen S; Löwenberg B; Sonneveld P; van Putten WL; Verhoef G; Verdonck LF; van Veldhoven M; Huijgens PC
    Leukemia; 1994 Jan; 8(1):6-10. PubMed ID: 8289499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
    Evensen SA; Brinch L; Wisløff F
    Tidsskr Nor Laegeforen; 1989 Jun; 109(19-21):2004-6. PubMed ID: 2749689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
    Archimbaud E; Leblond V; Michallet M; Cordonnier C; Fenaux P; Travade P; Dreyfus F; Jaubert J; Devaux Y; Fiere D
    Blood; 1991 May; 77(9):1894-900. PubMed ID: 2018832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy].
    Tsurumi H; Miura T; Yamada T; Sawada M; Nakamura N; Tomoda T; Takahashi T; Oyama M; Moriwaki H; Muto Y
    Rinsho Ketsueki; 1995 Jul; 36(7):657-64. PubMed ID: 7563593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
    Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
    J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
    Mariańska B; Apel D; Seferyńska I; Maj S
    Wiad Lek; 1998; 51(1-2):42-5. PubMed ID: 9608830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
    Price SL; Lancet JE; George TJ; Wetzstein GA; List AF; Ho VQ; Fernandez HF; Pinilla-Ibarz J; Kharfan-Dabaja MA; Komrokji RS
    Leuk Res; 2011 Mar; 35(3):301-4. PubMed ID: 21109304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
    Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
    Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
    Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
    Amadori S; Arcese W; Isacchi G; Meloni G; Petti MC; Monarca B; Testi AM; Mandelli F
    J Clin Oncol; 1991 Jul; 9(7):1210-4. PubMed ID: 2045861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
    Lee YG; Kwon JH; Kim I; Yoon SS; Lee JS; Park S
    Eur J Haematol; 2014 Jun; 92(6):478-84. PubMed ID: 24460733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.